MS gray matter loss reveals network-based mechanisms
-
By
-
Andrea Surnit
-
November 16, 2026
-
5 min
By
Andrea Surnit
November 16, 2026
The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.
June 15, 2026
Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.
March 4, 2026